Sus Clinicals, Inc.

We are delighted that Jessicca Rege is joining Sus Clinicals, Inc. as our next CEO.    Dr. Rege brings deep scientific expertise and a demonstrated track record of cross-functional business and scientific leadership, from start-ups to major global pharmaceutical players.     “I am thrilled to be joining the Sus Clinicals team,” said Dr. Rege. “My passion is to accelerate transformative research and therapeutics into the clinic, with the hope to save lives. To bring the qualified and FDA cleared Oncopig® platform to more researchers across the industry including medical devices, diagnostics and pharmaceuticals is a wonderful opportunity professionally and for the patients we all serve.”    Most recently Dr. Rege was Chief Development Officer of Mural Oncology and was instrumental in leading the public offering of the company. Prior to Mural she served as VP, Head of Clinical Development, Oncology at Alkermes. Over her career she has held positions with increasing responsibility in leading organizations including research and development, regulatory, operations, manufacturing, along with impressive track records in business development, M&As and fundraising. She has held multiple leadership roles in larger pharmaceuticals companies, all with significant oncology portfolios, including Daiichi Sankyo US, Eli Lilly and Company and Eisai US, to name a few.    “Dr. Rege’s educational background, with a Ph.D. in Pharmaceutical Sciences specializing in pharmacogenomics, her extensive pharmaceutical experience, and her superb leadership skills all position her well to take Sus Clinicals to the next level,” said Jeff Weedman, Board Chair and Co-Founder of the Company. Sus Clinicals accelerates development of life-saving cancer therapeutics through proprietary pig-based pre-clinical testing services. Known as the Oncopig Cancer Model®, this highly predictive approach can more quickly identify drugs, diagnostics and devices that have the highest potential for success in human clinical trials. 

Lawrence Schook opened today's #SBR2024 by sharing his reflections on progress since the first Swine in Biomedical Research conference in 1995. Looking ahead, Larry encouraged the group to continue efforts to create porcine biomedical research models even more reflective of human diseases, phenotypes, etc. We at Sus Clinicals, Inc. along with our many academic and industry collaborators are proud to play a role in helping accelerate life saving therapeutics "from bench to bedside."

We at Sus Clinicals, Inc. are delighted to participate in this year's Swine in Biomedical Research Conference #SBR2024, hosted by University of Wisconsin-Madison at their beautiful lakeside campus. Hundreds of the world's leading experts in porcine-based research will convene for the next four days to share their latest learnings to help advance breakthrough biomedical therapeutics. We are proud to be a sponsor of #SBR2024.

We're delighted that Dr. Kyle Schachtschneider, VP of R&D/Services, will present updates on our Oncopig Cancer Model® at next week's Society of Interventional Radiology Annual Meeting #SIR24SLC. This includes our liver and lung cancer models for device-based therapeutic studies, as well as a liver radioembolization study, co-presented with Dr. Aravind Arepally of ABK Biomedical Inc. This Sus Clinicals, Inc. team is proud to be working with remarkable cancer researchers in their mission to accelerate breakthrough therapeutics, to help save lives.  

Sus Clinicals, Inc. announced today that Dr. Lawrence Schook has been elected to the Company’s Board of Directors.   “I’m delighted that my friend and co-founder has joined the Board,” said Jeff Weedman, Co-Founder, CEO and Chair, Board of Directors. “I recall vividly when I met Larry, and he told me of the work he and his University of Illinois Urbana-Champaign team were doing to accelerate cancer research with a novel preclinical porcine model. We both saw the potential not only to create a company together, but to help cancer researchers save lives.”   Sus Clinicals accelerates qualification of life-saving cancer therapeutics through proprietary pig-based pre-clinical testing services, the Oncopig Cancer Model®.   “I’m honored to be joining the Board” said Dr. Schook. “Our whole team has made such tremendous progress since we stood up the Company in 2020. With FDA clearance and growing experience with our Oncopig® platform, I’m excited to continue our efforts to scale this capability broadly.”   In addition to Weedman, remaining on the Board are Geoffrey Marshall, CFO, and Steve Baggott, COO. Marshall and Baggott lead the Company’s commercial operations, and are based in Cincinnati, Ohio. Most of the Company’s scientific and technical team is based in facilities at the University of Illinois Chicago Incubator Laboratory Facility, where the bulk of the Company’s research is conducted.   In his role as a leader in the porcine research space, Dr. Schook led the global team which sequenced the pig genome in 2012. This work led to important foundational knowledge that supported the creation of the Oncopig Cancer Model.    Dr. Schook currently serves on the Albion College Board of Trustees, where he is a member of the executive committee and co-chairs the People and Talent Committee.

We are delighted that Kyle Schachtschneider, Vice President of R&D and Services for Sus Clinicals, Inc. will present exciting research from the Oncopig Cancer Model® at the Society of Interventional Oncology Annual Meeting later this month. Entitled “The Oncopig hepatocellular carcinoma (HCC) model as a tool for locoregional therapeutic studies,” Dr. Schachtschneider will share this research on Sunday, January 28 during presentations beginning at 3:30pm. HCC is an aggressive disease, often with a poor prognosis. Locoregional therapies (LRTs) are widely used for liver cancer treatment, and large animal models can support evaluation of new LRTs. The Oncopig Cancer Model is an ideal platform for such research, with induction of HCC on demand, yielding tumors virtually indistinguishable from their human counterparts, just two weeks post induction. As such, the Oncopig provides an ideal bridge between early mouse-based research and expensive human trials, helping cancer researchers move promising new therapies to the clinic faster. Dr. Schachtschneider, a widely published expert on the pig as a biomedical research platform, and other Sus Clinicals representatives will be at SIO and available for discussions with attendees who may be interested in learning more about Oncopig-based capabilities. Or contact us at info@susclinicals.com.